

# CITATION REPORT

List of articles citing

## Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

DOI: 10.1093/jnci/djw272

Journal of the National Cancer Institute, 2017, 109, .

**Source:** <https://exaly.com/paper-pdf/66754106/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
172	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , <b>2017</b> , 28, 958-968	10.3	53
171	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , <b>2017</b> , 28, 824-830	10.3	31
170	TAS-102 and the quest for predictive biomarkers. <b>2017</b> , 2, e000263		3
169	Whose side are you on?. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1685-1686	10.3	1
168	CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1227-1234	10.3	49
167	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2018</b> , 42, 396-402	2.4	11
166	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. <b>2018</b> , 67, 1168-1180		111
165	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <b>2018</b> , 4, e173695		37
164	MiR-216b inhibits pancreatic cancer cell progression and promotes apoptosis by down-regulating. <b>2018</b> , 14, 1321-1332		19
163	Prognostic value of the combination of microsatellite instability and mutation in colorectal cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 3911-3929	3.6	15
162	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. <b>2018</b> , 19, 31		16
161	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <b>2018</b> , 24, 4745-4753		14
160	Colorectal Cancers: An Update on Their Molecular Pathology. <i>Cancers</i> , <b>2018</b> , 10,	6.6	86
159	Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. <b>2018</b> , 6,		95
158	Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2018</b> , 33, 1173-1181	3	4
157	Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?. <b>2018</b> , 143, 2342-2350		5
156	Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. <b>2019</b> , 144, 841-847		12

155	BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. <b>2019</b> , 38, 6752-6766		30
154	External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. <i>BMC Cancer</i> , <b>2019</b> , 19, 681	4.8	10
153	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 120, 729-735	2.8	9
152	Subtyping of microsatellite instability-high colorectal cancer. <b>2019</b> , 17, 79		20
151	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 434-442	8.7	26
150	Colorectal cancer. <b>2019</b> , 394, 1467-1480		1051
149	Advances in the therapy of BRAF metastatic colorectal cancer. <b>2019</b> , 19, 823-829		2
148	Preoperative inflammatory response as prognostic factor of patients with colon cancer. <b>2019</b> , 404, 731-741		3
147	Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia. <b>2019</b> , 157, 949-966.e4		105
146	Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial. <b>2019</b> , 26, 3561-3567		3
145	Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. <b>2019</b> , 145, 1625-1634		28
144	Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. <b>2019</b> , 8, 3623-3635		23
143	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 82-93	7.5	7
142	RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. <b>2019</b> , 145, 2580-2593		16
141	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 75, 1-11	14.4	30
140	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. <b>2019</b> , 208, 63-72		7
139	Implication of Microsatellite Instability Pathway in Outcome of Colon Cancer in Moroccan Population. <b>2019</b> , 2019, 3210710		6
138	Clinical validation of coexisting driver mutations in colorectal cancers. <b>2019</b> , 86, 12-20		7

137	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <b>2019</b> , 72, 135-139		17
136	Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. <b>2019</b> , 25, 349-359		12
135	Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. <b>2019</b> , 17, 402-410.e2		30
134	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <b>2020</b> , 146, 94-102		15
133	Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <b>2020</b> , 25, e266-e275		2
132	Biomarker-guided therapy for colorectal cancer: strength in complexity. <b>2020</b> , 17, 11-32		103
131	Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis. <b>2020</b> , 97, 25-38		11
130	The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation. <b>2020</b> , 44, 151445		3
129	MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis. <b>2020</b> , 216, 152791		14
128	High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer. <b>2020</b> , 43, 237-247		3
127	Construction and Characterization of KRAS Immune Lipid Magnetic Balls for Colorectal Cancer Circulating Tumor Cells. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 10067-10075	3.6	0
126	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1291-1305	10.3	165
125	Adjuvant chemotherapy in colon cancer: state of the art and future perspectives. <b>2020</b> , 32, 370-376		3
124	Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis. <b>2020</b> , 22, 1231-1244		13
123	Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 122, 1106-1113	2.8	1
122	The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. <b>2020</b> , 21,		3
121	Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 579478	5.3	2
120	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1

119	Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
118	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. <b>2021</b> , 52, 932-939		
117	Genomic Strategies for Personalized Cancer Therapy. <b>2020</b> , 1-60		
116	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. <b>2020</b> , 4, 635-645		2
115	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <b>2020</b> , 13, 100795		14
114	Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients. <b>2020</b> , 69, 2533-2546		9
113	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <b>2020</b> , 69, 681-690		42
112	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <b>2020</b> , 4,		4
111	The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database. <b>2020</b> , 24, 1402-1410		8
110	Mucinous borderline ovarian tumors with BRAF mutation may have low risk for progression to invasive carcinomas. <b>2020</b> , 302, 487-495		4
109	Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. <b>2020</b> , 27, 5074-5083		8
108	Encorafenib, binimetinib and cetuximab combined therapy for patients with mutant metastatic colorectal cancer. <b>2020</b> , 16, 161-173		6
107	Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. <i>Cancers</i> , <b>2020</b> , 12,	6.6	59
106	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. <b>2020</b> , 17, 277-290		1
105	Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. <b>2020</b> , 77, 340-350		13
104	Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. <b>2021</b> , 14, 100945		1
103	Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. <b>2021</b> , 148, 1731-1742		4
102	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 101-112	7.5	4

101	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. <b>2021</b> , 15, 65-79		1
100	Proposal for a post-operative surveillance strategy for stage I colorectal cancer patients based on a novel recurrence risk stratification: a multicenter retrospective study. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 67-74	3	1
99	Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. <b>2021</b> , 11, 441		5
98	Evolution of rectal cancer treatments. Clinical evaluation of predictors for radiosensitivity. <b>2021</b> , 10, 53		
97	Role of DNA Mismatch Repair Genes in Colorectal Cancer. <b>2021</b> , 209-223		
96	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	10
95	The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer. <b>2021</b> , 112, 1545-1555		
94	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <b>2021</b> , 39, 642-651		27
93	Targeting KRAS in Colorectal Cancer. <b>2021</b> , 23, 28		8
92	Bacterial-Driven Inflammation and Mutant Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy. <b>2021</b> , 11, 1792-1807		13
91	Stratification of Chemotherapy-Treated Stage III Colorectal Cancer Patients Using Multiplexed Imaging and Single Cell Analysis of T Cell Populations.		
90	Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report. <b>2021</b> , 16, e0248522		2
89	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 74-83	7.5	8
88	Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
87	Relationship between mismatch repair protein, , , gene expression and clinicopathological characteristics in elderly colorectal cancer patients. <b>2021</b> , 9, 2458-2468		1
86	Enhancing the landscape of colorectal cancer using targeted deep sequencing. <b>2021</b> , 11, 8154		6
85	Pulmonary metastasectomy in colorectal carcinoma. <b>2021</b> , 13, 2628-2635		2
84	Multi-omics characterization and validation of MSI-related molecular features across multiple malignancies. <b>2021</b> , 270, 119081		1

83	Effect of sidedness on survival among patients with early-stage colon cancer: a SEER-based propensity score matching analysis. <b>2021</b> , 19, 127			3
82	Precision oncology in metastatic colorectal cancer - from biology to medicine. <b>2021</b> , 18, 506-525			27
81	Targeting BRAF and RAS in Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,		6.6	5
80	Serum Tumor Markers Combined With Clinicopathological Characteristics for Predicting MMR and KRAS Status in 2279 Chinese Colorectal Cancer Patients: A Retrospective Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 582244		5.3	1
79	Strategies to tackle RAS-mutated metastatic colorectal cancer. <b>2021</b> , 6, 100156			7
78	SK4 oncochannels regulate calcium entry and promote cell migration in KRAS-mutated colorectal cancer. <b>2021</b> , 96, 102384			4
77	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <b>2021</b> , 27, 4768-4780			5
76	Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. <b>2021</b> , 11, 14609			2
75	CoBRA: Containerized Bioinformatics Workflow for Reproducible CHIP/ATAC-seq Analysis. <b>2021</b> ,			4
74	Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 1-3	7.5		1
73	SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. <b>2021</b> , 40, 6034-6048			0
72	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1496-1510		10.3	7
71	Survival rates and prognostic factors in right- and left-sided colon cancer stage I-IV: an unselected retrospective single-center trial. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 2683-2696		3	0
70	Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1034-1040		3.3	0
69	The current understanding on the impact of KRAS on colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 140, 111717		7.5	17
68	Construction and Analysis of a Colorectal Cancer Prognostic Model Based on N6-Methyladenosine-Related lncRNAs. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 698388		5.7	0
67	KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,		9.7	4
66	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. <i>Cancers</i> , <b>2021</b> , 13,		6.6	3

65	Prognostic Value of Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients. <i>Journal of Cancer</i> , <b>2021</b> , 12, 5331-5337	4.5	1
64	CoBRA: Containerized Bioinformatics workflow for Reproducible CHIP/ATAC-seq Analysis - from differential peak calling to pathway analysis.		3
63	and Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. <i>Oncology Research</i> , <b>2021</b> , 28, 631-644	4.8	4
62	Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study. <i>Saudi Journal of Medicine and Medical Sciences</i> , <b>2019</b> , 7, 16-21	0.9	16
61	Standardized Pathology Report for Colorectal Cancer, 2nd Edition. <i>Journal of Pathology and Translational Medicine</i> , <b>2020</b> , 54, 1-19	2.9	13
60	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. <i>World Journal of Gastrointestinal Oncology</i> , <b>2020</b> , 12, 808-832	3.4	16
59	Colorectal liver metastases: Current management and future perspectives. <i>World Journal of Clinical Oncology</i> , <b>2020</b> , 11, 761-808	2.5	24
58	Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma. <i>Aging</i> , <b>2021</b> , 13, 23072-23095	5.6	6
57	Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 754881	5.3	4
56	Loss of SMARCB1 expression in colon carcinoma. <i>Cancer Biomarkers</i> , <b>2020</b> , 27, 399-406	3.8	0
55	Inhibition of Generates Cetuximab Resistance through c-Met and Akt. <i>BioMed Research International</i> , <b>2020</b> , 2020, 2046248	3	0
54	Biomarkers in colon cancer and its clinical implications. <i>Journal of Current Oncology</i> , <b>2020</b> , 3, 66	0.1	
53	[Neoadjuvant and adjuvant therapy of resectable colon cancer - Current standards and developments]. <i>Deutsche Medizinische Wochenschrift</i> , <b>2021</b> , 146, 1457-1467	0	0
52	Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS Mutations.		
51	Clinicopathological Features Combined With Immune Infiltration Could Well Distinguish Outcomes in Stage II and Stage III Colorectal Cancer: A Retrospective Study.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 776997	5.3	0
50	Number of negative lymph nodes with a positive impact on survival of stage III colon cancer; a retrospective observation study for right side and left side colon.. <i>BMC Cancer</i> , <b>2022</b> , 22, 126	4.8	0
49	Machine Learning-Based Prognostic Prediction Models of Non-Metastatic Colon Cancer: Analyses Based on Surveillance, Epidemiology and End Results Database and a Chinese Cohort.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 25-35	3.6	0
48	Radiomic analysis for predicting prognosis of colorectal cancer from preoperative F-FDG PET/CT.. <i>Journal of Translational Medicine</i> , <b>2022</b> , 20, 66	8.5	1

47	Immunotherapy in the Treatment of Advanced Colorectal Cancer. <b>2022</b> , 1		
46	Systemic treatment of localized colorectal cancer. <b>2022</b> , 257-271		
45	Clinical Significance of Genetic Variants in Colon Cancer. <b>2022</b> , 69-91		
44	Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer.. <i>Current Oncology</i> , <b>2022</b> , 29, 1370-1389	2.8	0
43	KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.. <i>Journal of Surgical Oncology</i> , <b>2022</b> ,	2.8	0
42	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. <i>Current Issues in Molecular Biology</i> , <b>2022</b> , 44, 1332-1352	2.9	0
41	Combined Estrogen Alpha and Beta Receptor Expression Has a Prognostic Significance for Colorectal Cancer Patients.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 739620	4.9	0
40	The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 1353-1369	3.6	0
39	Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.. <i>Journal of Gastrointestinal Oncology</i> , <b>2021</b> , 12, 2775-2787	2.8	0
38	Pathological Features and Prognostication in Colorectal Cancer.. <i>Current Oncology</i> , <b>2021</b> , 28, 5356-5383	2.8	2
37	Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer.. <i>Cancer Biomarkers</i> , <b>2021</b> ,	3.8	0
36	Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy.. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
35	Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	1
34	Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer.. <i>Journal of Clinical Laboratory Analysis</i> , <b>2022</b> , e24444	3	1
33	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. <i>European Journal of Cancer</i> , <b>2022</b> , 168, 34-40	7.5	0
32	Table_1.docx. <b>2020</b> ,		
31	Table_2.docx. <b>2020</b> ,		
30	Table_3.docx. <b>2020</b> ,		

29	Diagnostic and therapeutic biomarkers in colorectal cancer: a review.. <i>American Journal of Cancer Research</i> , <b>2022</b> , 12, 661-680	4.4	
28	The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.. <i>Annals of Translational Medicine</i> , <b>2022</b> , 10, 491	3.2	1
27	Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
26	Minireview. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2022</b> , 101983	2.4	0
25	Colon Cancer Classification and Prognosis Prediction Based on Genomics Multi-Features. <i>SSRN Electronic Journal</i> ,	1	
24	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 102433	14.4	0
23	Role of Long Noncoding RNA Regulator of Reprogramming in Colon Cancer Progression via Epidermal Growth Factor Receptor Signaling. <b>2022</b> , 21, 153303382211147		1
22	Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. <b>2022</b> , 22,		1
21	Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance]. <b>2022</b> ,		1
20	Isparta Burdur Yöresindeki Kolon Kanseri Hastaların Demografik ve Klinik Özellikleri.		
19	MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer. <b>2022</b> , 7, 100559		0
18	The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers. <b>2022</b> , 11, 5132		0
17	High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. 12,		1
16	Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. <b>2022</b> , 11, 3744		0
15	Biomarkers in the development of individualized treatment regimens for colorectal cancer. 9,		1
14	Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study. <b>2022</b> ,		0
13	Artificial Intelligence-Based Prediction of Recurrence after Curative Resection for Colorectal Cancer from Digital Pathological Images.		0
12	Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer. 2203757		0

- 11 Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach. **2023**, 13, 33 ○
- 10 Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors. **2023**, 13, 395 ○
- 9 Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. **2023**, 18, ○
- 8 The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers. ○
- 7 ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. ○
- 6 Deviating Alternative Splicing as a Molecular Subtype of Microsatellite Stable Colorectal Cancer. **2023**, ○
- 5 Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. **2023**, 15, 1473 ○
- 4 KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China. **2023**, 102, e33115 ○
- 3 Aerobic glycolysis in colon cancer is repressed by naringin via the HIF1A pathway. **2023**, 24, 221-231 ○
- 2 Effect of microsatellite instability on histopathological parameters and prognosis in colon cancers. **2023**, 48, 1-10 ○
- 1 The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers. ○